Dabur India anticipates modest revenue growth for the first quarter of fiscal year 2026. Unseasonal rains impacted the beverages segment. Home and Personal Care division shows strength, especially in urban markets. Dabur Honitus leads healthcare growth. International business delivers double-digit growth. Nuvama maintains a 'Buy' rating with a target price of Rs 615.
rallied 2.6% to their day’s high of Rs 508.05 on the BSE on Monday, July 7, after the company released its business update for the quarter ended June 30, 2025 (
Q1 FY26).The update, released ahead of its detailed financial results, reflects a mixed performance across key segments, projecting low single-digit consolidated
revenue growth.
Further, Dabur has also flagged a decline in its beverages portfolio, impacted by unseasonal rains and a short summer. While Activ Juices and Activ Coconut Water saw mid-teen growth, overall weakness in the segment weighed on consolidated performance. As a result, operating profit growth is also expected to be marginal.
The Indian FMCG major said that volume growth in urban markets aided sequential demand recovery, particularly in its Home and Personal Care (HPC) division, which saw strong performance in oral, home, and skin care categories.
Notable brands like Dabur Red Toothpaste, Odonil, Odomos, and Gulabari contributed to market share gains.
In the
healthcare space, brands such as Dabur Honey, Hajmola, Honitus, and Dabur Health Juices posted robust double-digit growth, with Dabur Honitus leading the pack with over 40% growth.Organised trade channels including e-commerce, quick commerce, and modern trade continued their upward momentum.The company’s international business delivered double-digit constant currency growth, driven by strong performances in key markets such as MENA, Turkey, Bangladesh, and the US Namaste business.
Despite near-term challenges, Dabur remains optimistic, citing above-average monsoon, easing inflation, and a revamped strategic vision as tailwinds for the upcoming quarters.
Also read: Jane Street aftermath: 4 stocks suffer Rs 12,000 crore wipeout in collateral damage
After the Q1 update, domestic brokerage firm Nuvama has maintained a 'Buy' rating on Dabur India with a target price of Rs 615.
The brokerage noted that the Q1FY26 update was largely in line with estimates. Dabur's consolidated revenue is expected to grow by 2.1% year-on-year (YoY), a slowdown compared to 7% growth in Q1FY25. The domestic business is projected to decline by 3% YoY (vs +7% in Q1FY25), while the international business is expected to expand by a strong 17% YoY.
The Home and Personal Care (HPC) segment is expected to perform well, and the healthcare division is likely to deliver double-digit growth, led by Dabur Honitus. In the beverage portfolio, Activ Juices and Coconut Water are expected to grow in mid-teens in Q1FY26E.
Overall, the stock is likely to perform well in the near term, according to Nuvama.
(: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
_1751880097.jpeg)
